OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Ravandi, Farhad [1 ]
Carraway, Hetty E. [2 ]
Taningco, Lilia [3 ]
Dilley, Kimberley [3 ]
Laille, Eric [3 ]
Gong, Jing [3 ]
de Menezes, Daniel Lopes [3 ]
Wei, Andrew H. [4 ,5 ]
机构：
[1] Univ Texas M D Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Monash Univ, Melbourne, Australia
[5] Alfred Hosp, Melbourne, Australia
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147293
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2314
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Laille, Eric
    Gong, Jing
    Prebet, Thomas
    De Menezes, Daniel Lopes
    Wei, Andrew H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    [J]. BLOOD, 2021, 138
  • [3] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    [J]. CANCERS, 2022, 14 (08)
  • [4] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    [J]. BLOOD, 2022, 140 : 9036 - 9037
  • [5] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    [J]. BLOOD, 2022, 140
  • [6] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Jaddaoui, Samiha
    Bencharef, Hanaa
    Addakiri, Sara
    Dehbi, Hind
    Lamchahab, Mouna
    Quessar, Asmaa
    Madani, Abdellah
    Oukkache, Bouchra
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256
  • [7] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
    Jonas, Brian A.
    Hou, Jing-Zhou
    Roboz, Gail J.
    Alvares, Caroline L.
    Jeyakumar, Deepa
    Edwards, John R.
    Erba, Harry P.
    Kelly, Richard J.
    Roellig, Christoph
    Fiedler, Walter
    Brackman, Deanna
    Siddani, Satya R.
    Chyla, Brenda
    Hilger-Rolfe, Jacqueline
    Watts, Justin M.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
  • [8] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Konopleva, Marina
    Maiti, Abhishek
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Loghavi, Sanam
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Golez, Michelle
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Ning, Jing
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    [J]. BLOOD, 2021, 138
  • [9] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Zeidan, Amer M.
    Westermann, Joerg
    Kovacsovics, Tibor
    Assouline, Sarit
    Schuh, Andre C.
    Kim, Hee-Je
    Macias, Gabriela Rodriguez
    Sanford, David
    Luskin, Marlise R.
    Stein, Eytan M.
    Malek, Kamel
    Lyu, Jiaying
    Stegert, Mario
    Esteve, Jordi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255
  • [10] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas K.
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
12345